The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
Progress in the study of pharmacoeconomics of etanercept in the treatment for ankylosing spondylitis
Author(s): 
Pages: 189-193
Year: Issue:  3
Journal: World Clinical Drugs

Keyword:  etanerceptankylosing spondylitispharmacoeconomics;
Abstract: The main clinical treatment for ankylosing spondylitis(AS) is using tumor necrosis factor(TNF)-α inhibitors. etanercept, as a recombinant dimeric fusion protein that competitively antagonises the action of TNF-α upon its receptor has been widely used in clinical practice and achieved great effect. In this review, the authors have reviewed systemically from pharmacoeconomics point of viewing etanercept for AS, including its clinical benefi t and economic burden and so on.
Related Articles
No related articles found